Skip to content
6-K

Foreign Interim / Material

INTELLIPHARMACEUTICS INTERNATIONAL INC.

0001654954-22-013767

← back to feed
Filed
Oct 14, 2022 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Capex Q3 2022 · Aug 31, 2022 $0
Capex Q3 2022 · Aug 31, 2022 $0
Capex Q3 2022 · Aug 31, 2021 $0
Capex Q3 2022 · Aug 31, 2021 $0
Cash And Equivalents Q3 2022 · Aug 31, 2022 $79.65K
Cash And Equivalents Q3 2022 · Nov 30, 2021 $771.95K
Stockholders Equity Q3 2022 · Aug 31, 2022 −$10.15M
Stockholders Equity Q3 2022 · Aug 31, 2021 −$6.17M
Stockholders Equity Q3 2022 · Nov 30, 2020 −$6.31M
Total Liabilities Q3 2022 · Aug 31, 2022 $11.59M
Total Liabilities Q3 2022 · Nov 30, 2021 $10.25M
Current Assets Q3 2022 · Aug 31, 2022 $554.83K
Current Assets Q3 2022 · Nov 30, 2021 $1.1M
Total Assets Q3 2022 · Aug 31, 2022 $1.44M
Total Assets Q3 2022 · Nov 30, 2021 $2.1M
Revenue Q3 2022 · Aug 31, 2022 $19.07K
Revenue Q3 2022 · Aug 31, 2022 $36.05K
Revenue Q3 2022 · Aug 31, 2021 $0
Revenue Q3 2022 · Aug 31, 2021 $0
Operating Cash Flow Q3 2022 · Aug 31, 2021 −$1.36M
Operating Cash Flow Q3 2022 · Aug 31, 2021 −$2.13M
Rd Expense Q3 2022 · Aug 31, 2021 $723.22K
Rd Expense Q3 2022 · Aug 31, 2021 $1.66M
Net Income Q3 2022 · Aug 31, 2021 −$3.19M
Operating Income Q3 2022 · Aug 31, 2021 −$1.08M
Operating Income Q3 2022 · Aug 31, 2021 −$2.78M